RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Biotechnology Assets P/S 2024

Biotechnology Assets P/S

6.64

Biotechnology Assets Dividend yield

Ticker

BST.MC

ISIN

ES0184980003

WKN

A1XB95

As of Jun 3, 2024, Biotechnology Assets's P/S ratio stood at 6.64, a 7.62% change from the 6.17 P/S ratio recorded in the previous year.

The Biotechnology Assets P/S history

Biotechnology Assets Aktienanalyse

What does Biotechnology Assets do?

ADL Bionatur Solutions SA is a Swiss company specializing in the development and production of natural ingredients for the food, cosmetics, and pharmaceutical industries. The company was founded in 2000 and has since had an impressive success story. ADL Bionatur Solutions SA's business model is based on the use of plants and microorganisms to extract high-quality natural active ingredients. The company employs environmentally friendly methods and sustainable production practices that meet the needs of society and nature alike. One of ADL Bionatur Solutions SA's main sectors is the production of natural flavors and colorants for the food industry. Depending on customer preferences, color pigments are extracted from fruits, vegetables, or other plants to color food products with natural ingredients. Natural flavors are also isolated using plant extracts and other natural sources. These products are particularly sought after because they are not only healthier than synthetic alternatives but also provide consumers with a better feeling. Another significant sector of ADL Bionatur Solutions SA is the development of cosmetics based on natural ingredients. For example, extracts from algae, flowers, or herbs are used to create skincare products that are gentle on the skin while still being highly effective. Products targeting signs of aging or acne are also based on natural ingredients from ADL Bionatur Solutions SA. In addition to these two main sectors, ADL Bionatur Solutions SA also offers products for the pharmaceutical industry. The company focuses on developing active ingredients based on natural substances that can be used to treat various diseases. Sustainability is also a key focus here, as naturally derived active ingredients are not only healthier but also have a higher biological availability. In addition to these main sectors, ADL Bionatur Solutions SA provides consulting services to customers. This includes the development of tailored natural solutions and support for product certification according to the highest international standards. Overall, in recent years, ADL Bionatur Solutions SA has become one of the world's leading companies in the field of natural ingredients. With a wide portfolio of products and services and a strong focus on sustainability and environmental compatibility, the company is well-positioned to benefit from the ongoing trend towards natural and healthier products. Biotechnology Assets ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Biotechnology Assets's P/S Ratio

Biotechnology Assets's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Biotechnology Assets's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Biotechnology Assets's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Biotechnology Assets’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Biotechnology Assets Stock

What is the price-to-earnings ratio of Biotechnology Assets?

The price-earnings ratio of Biotechnology Assets is currently 6.64.

How has the price-earnings ratio of Biotechnology Assets changed compared to last year?

The price-to-earnings ratio of Biotechnology Assets has increased by 7.62% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Biotechnology Assets high compared to other companies?

Yes, the price-to-earnings ratio of Biotechnology Assets is high compared to other companies.

How does an increase in the price-earnings ratio of Biotechnology Assets affect the company?

An increase in the price-earnings ratio of Biotechnology Assets would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Biotechnology Assets affect the company?

A decrease in the price-earnings ratio of Biotechnology Assets would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Biotechnology Assets?

Some factors that influence the price-earnings ratio of Biotechnology Assets are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Biotechnology Assets pay?

Over the past 12 months, Biotechnology Assets paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biotechnology Assets is expected to pay a dividend of 0 EUR.

What is the dividend yield of Biotechnology Assets?

The current dividend yield of Biotechnology Assets is .

When does Biotechnology Assets pay dividends?

Biotechnology Assets pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biotechnology Assets?

Biotechnology Assets paid dividends every year for the past 0 years.

What is the dividend of Biotechnology Assets?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biotechnology Assets located?

Biotechnology Assets is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biotechnology Assets kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biotechnology Assets from 6/3/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/3/2024.

When did Biotechnology Assets pay the last dividend?

The last dividend was paid out on 6/3/2024.

What was the dividend of Biotechnology Assets in the year 2023?

In the year 2023, Biotechnology Assets distributed 0 EUR as dividends.

In which currency does Biotechnology Assets pay out the dividend?

The dividends of Biotechnology Assets are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Biotechnology Assets

Our stock analysis for Biotechnology Assets Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotechnology Assets Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.